Results 271 to 280 of about 490,842 (303)

The Impact of Surfactant Protein‐D Gene Polymorphism on COVID‐19 Clinical Outcomes

Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Background COVID‐19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), presents a broad spectrum of clinical manifestations, ranging from asymptomatic cases to severe, life‐threatening respiratory complications. Pulmonary surfactant‐associated protein D (SP‐D) is a critical component of pulmonary immune defense.
Nadia Nasirzadeh Kolsari, Azarakhsh Azaran, Roya Pirmoradi, Maryam Moradi, Roohangiz Nashibi, Shahram Jalilian   +5 more
wiley   +1 more source

Critical illness in immunocompromised patients: insights into relapse or persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): case series report. [PDF]

J Med Case Rep
Hernández-Ortiz OH, Llano JF, Sánchez AM, Jaimes F, Moreno AM, Perez-Restrepo LS, Usuga J, Camacho E, Osorio JE, Hernández-Ortiz JP.   +9 more
europepmc   +1 more source

The PTP4A3 inhibitor KVX-053 reduces Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virulence, inflammation, and development of acute lung injury in K18-hACE2 mice. [PDF]

Respir Res
Colunga-Biancatelli RML, Solopov PA, Woodson CM, Allen IC, Akhrymuk I, Akhrymuk M, Heath BN, Ivester HM, Day T, Austin DE, Kehn-Hall K, Lazo JS, Sharlow ER, Catravas JD.   +13 more
europepmc   +1 more source

Subclinical and long-term effects of severe acute respiratory syndrome coronavirus 2 infection in Danish farmed mink: implications for disease surveillance. [PDF]

Acta Vet Scand
Quaade ML, Jensen MM, Rasmussen TB, Jensen TK, Hammer AS.   +4 more
europepmc   +1 more source

Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18-55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial. [PDF]

J Infect Dis
Chappell KJ, Mordant FL, Amarilla AA, Modhiran N, Liang B, Li Z, Lackenby JA, Jaberolansar N, O'Donnell J, Kienzle V, Kommajosyula V, Tardiota N, Bennet JK, Henderson CL, Dalrymple RL, Goh J, Hoger K, Gillard M, Jones ML, Hughes K, Hughes B, Barnes J, Reading PC, Ranasinghe C, Subbarao K, Munro TP, Young PR, Watterson D.   +27 more
europepmc   +1 more source

Recovery from Myalgic Encephalomyelitis/Chronic Fatigue syndrome developed after severe acute respiratory syndrome coronavirus 2 vaccination: A case report. [PDF]

PCN Rep
Kurotori I, Sasao W, Abe M.
europepmc   +1 more source

Severe acute respiratory syndrome coronavirus 2 infection unevenly impacts metabolism in the coronal periphery of the lungs. [PDF]

iScience
Laro J, Xue B, Zheng J, Ness M, Perlman S, McCall LI.   +5 more
europepmc   +1 more source

Detection of Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) on frequently touched surfaces in selected areas in Accra, Ghana. [PDF]

Ghana Med J
Asante IA, Magnusen V, Darban I, Oppong-Atuahene M, Quarcoo JA, Ntim NAA, Asamoah I, Sagoe KW, Commey JO, Adusei-Poku MA.   +9 more
europepmc   +1 more source

Arteriovenous Thrombosis among Severe Acute Respiratory Syndrome Coronavirus 2 Infected Patients: An Observational Study at a University Hospital.

Ann Afr Med
AlAmri AS, AlShahrani MS, Hejazi TM, Abualola HA, Samarah AT, Almuaigel MF, AlDawsar FA, AlRashidi NS, AlGhamdi MA, Kabbani AH.   +9 more
europepmc   +1 more source